Longeveron (LGVN) Liabilities and Shareholders Equity (2021 - 2026)
Longeveron's (LGVN) quarterly Liabilities and Shareholders Equity came in at $21.2 million in Q1 2026, up 1.74% year-on-year from $20.8 million in Q1 2025, and up 106.7% quarter-over-quarter from $10.3 million in Q4 2025.
Longeveron (LGVN) Liabilities and Shareholders Equity (2021 - 2026) Analysis & Trends
Longeveron's Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $21.2 million for Q1 2026.
- On a quarterly basis, Liabilities and Shareholders Equity rose 1.74% year-over-year to $21.2 million in Q1 2026; TTM through Mar 2026 was $63.8 million, a 33.36% decrease from a year earlier, with the FY2025 full-year figure at $10.3 million, down 59.85% from the prior year.
- Liabilities and Shareholders Equity improved to $21.2 million in Q1 2026 per LGVN's latest filing, from $10.3 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $29.9 million in Q3 2024 and bottomed at $9.7 million in Q1 2024.
- The 5-year median for Liabilities and Shareholders Equity is $18.2 million (2023), against an average of $18.5 million.
- Across the five-year window, Liabilities and Shareholders Equity surged 157.28% in 2024 and sank 59.85% in 2025, its largest moves.
- Year by year, Liabilities and Shareholders Equity stood at $27.4 million in 2022, then sank by 55.94% to $12.1 million in 2023, then soared by 111.61% to $25.6 million in 2024, then sank by 59.85% to $10.3 million in 2025, then jumped by 106.7% to $21.2 million in 2026.
- Per Business Quant, the three latest LGVN Liabilities and Shareholders Equity figures stand at $21.2 million (Q1 2026), $10.3 million (Q4 2025), and $15.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 311.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 78.88 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 8.55 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 39.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 26.48 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 40.87 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 811.27 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 10.03 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.25 Bn |
| 10 | Longeveron | 3.97 Mn | -11.79 Mn | 264,000.00 | 21.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.21 Mn |
| Dec 31, 2025 | 10.26 Mn |
| Sep 30, 2025 | 15.56 Mn |
| Jun 30, 2025 | 16.75 Mn |
| Mar 31, 2025 | 20.85 Mn |
| Dec 31, 2024 | 25.56 Mn |
| Sep 30, 2024 | 29.91 Mn |
| Jun 30, 2024 | 19.39 Mn |
| Mar 31, 2024 | 9.70 Mn |
| Dec 31, 2023 | 12.08 Mn |
| Sep 30, 2023 | 11.63 Mn |
| Jun 30, 2023 | 17.09 Mn |
| Mar 31, 2023 | 21.81 Mn |
| Dec 31, 2022 | 27.41 Mn |
| Dec 31, 2021 | 42.77 Mn |